EUROPROTEOME AG - the Human Cancer Proteomics Company - is a leading biomedical firm focusing on R&D and product development in the area of epithelial cancers. The company's mission is to provide the oncology market with diagnostic and prognostic tools, patient-specific therapies, and immunological tools. Its vision is to become the preferred partner for leading pharmaceutical and diagnostic companies as a source for validated targets and oncology know-how. In its research, EUROPROTEOME applies proteome technology to human epithelial cancers in order to identify specific gene expression patterns (targets / markers). The company operates a state-of-the-art high throughput proteomics and gene expression laboratory in the Biotech Park at Hennigsdorf/Germany (near Berlin). Since 1997, EUROPROTEOME has set up one of the world''s largest human tumor sample banks and cancer networks consisting of clinical and scientific researchers from several European and American research institutes and clinics. Its patented sample preparation method provides a unique source for highly purified human tissue samples. In combination with a well-standardized set of patient data the company has a privileged starting position for a leading position in the oncology market. EUROPROTEOME is among the few biotechnology firms able to bridge clinical, pathology-related, genomic, and proteomic information in the field of epithelial cancers. Using advanced bioinformatics, EUROPROTEOME can handle and integrate the vast amount of data produced.
Forschung & Lehre